Partner and co-founder of early stage life science venture firm Third Rock Ventures Mark Levin told the audience at a May 15 Manhattan Institute conference on The Digital Future of Molecular Medicine that he was excited about the emerging science but he sees a system-wide failure to fund and nurture innovative early-stage companies.
Levin's voice is one to be reckoned with. Over the past 38 years, he's worked as a project manager at...